On Thursday 19 October, the European Commission announced its unconditional approval of the acquisition of the US biotechnology company Seagen, which develops and markets targeted cancer therapies known as “antibody-drug conjugates”, by the US pharmaceutical company Pfizer. By acquiring sole control of Seagen through a share purchase, Pfizer aims to diversify its portfolio and strengthen its innovative medicines development business.
The transaction was notified to the Commission on...